Prescient Appendix 4E and 2015 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- PTX-200 Breast Cancer Trial Progresses
- Steven Yatomi-Clarke Appointed CEO
- December 2015 Appendix 4C - Quarterly
- Virax secures $3 million placement
Later from Prescient Therapeutics
- Appendix 4C - quarterly
- Appointment of Managing Director to Drive Cancer Programs
- Co-X-Gene Development Pipeline
- Disclosure Document
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics